论文部分内容阅读
作者对16(男15、女1)例慢性活动性肝炎(CAH)病人应用大剂量干扰素治疗作双盲研究。患者均符合:HBsAg阳性至少12个月,HBeAg及DNA-聚合酶(DNA-P)活力阳性,谷草转氨酶(AST)值正常,肝活检示CAH,HBcAg荧光免疫反应阳性。病人随机给予人白细胞干扰素或安慰剂(人体白蛋白)治疗。干扰素组8例第1周每日肌注12×10~6U干扰素,以后每周减半,至第6周止。治疗次日,所有16例均接种灭活的非人类流感病毒(Heql Neql)以观察外源性干扰素对原发性免疫反应之影响。
The authors conducted a double-blind study of 16 (15 male and 1 female) chronic active hepatitis (CAH) patients treated with high-dose interferon. The patients were all eligible for HBsAg positive for at least 12 months, HBeAg and DNA-P (DNA-P) positive, aspartate aminotransferase (AST) values were normal, liver biopsy showed CAH, HBcAg positive fluorescence immunoreaction. Patients were randomized to receive human leukocyte interferon or placebo (human albumin). Interferon group 8 patients in the first week of intramuscular injection of 12 × 10 ~ 6U daily interferon, then halved every week until the 6th week. On the next day of treatment, all 16 patients were vaccinated with inactivated non-human influenza virus (Heql Neql) to observe the effect of exogenous interferon on the primary immune response.